Fixed-dose combination of indapamide and amlodipine in the treatment of isolated systolic hypertension: analysis of the ARBALET study

Aim. To evaluate the effectiveness of single-pill combination of indapamide/ amlodipine in outpatients over 55 years of age with uncontrolled isolated systolic hypertension (ISH) in a real-world practice. Material and methods. Retrospective analysis of data from participants in the multicenter, open-label observational ARBALET study conducted in Russia among patients with grade 1-2 hypertension without prior antihypertensive therapy or blood pressure (BP) control while taking the medications. The efficacy of indapamide/ amlodipine combination was assessed by changes in office systolic BP (SBP) and the rate of achieving the target SBP level (<140 mm Hg) after 2 weeks, 1 month, and 3 months in four following age groups: 55-59 years, 60-69 years, 70-79 years, and ≥80 years. Results. The ARBALET study enrolled 2217 patients, of whom 626 had ISH and were included in this additional analysis (mean age 66,1±7,8 years; 165 men (26,4%)). The target SBP <140 mm Hg was achieved in 43%, 75%, and 93% of patients after 2 weeks, 1 month, and 3 months, respectively. Compared with the baseline, SBP decreased by 18,8±10,5 mm Hg, 27,2±10,6 mm Hg, and 31,8±9,9 mm Hg after 2 weeks, 1 month, and 3 months, respectively. The decrease in SBP after 3 months compared with the baseline in the subgroups 55-60 years, 60-69 years, 70-79 years, and ≥80 years was 30,3±9,4 mm Hg, 32,4±9,7 mm Hg, 32,5±10,7, and 28,9±9,6 mm Hg, respectively. Conclusion. Administration of indapamide/amlodipine combination is associated with a significant reduction in SBP and a high rate of target BP achievement in patients with ISH over 55 years of age in a real-world practice.